Manufacturer
Brand Dragon Pharma
Last Lab Tested See COA
Core Information
Substance Ovagen (EDL)
Classification Khavinson cytogen tripeptide bioregulator
Active Half-Life Short — typical of ultrashort peptides
Typical Dosage 100–500 mcg per research protocol
Effects & Properties
Water Retention No
Aromatization No
Hepatotoxicity No
Hair Loss Risk (HBR) No
Acne No
Dragon Pharma Ovagen — EDL Tripeptide Bioregulator
Dragon Pharma Ovagen is the liver and gastrointestinal-targeted compound in the Khavinson cytogen peptide series — a synthetic tripeptide bioregulator composed of the amino acid sequence Glutamic acid-Aspartic acid-Leucine, abbreviated in scientific literature as EDL. Developed within Professor Vladimir Khavinson's peptide bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, Dragon Pharma Ovagen carries the structural properties that define the Khavinson cytogen class: a compact three-residue architecture providing high membrane permeability and nuclear accessibility, enabling direct chromatin interaction and tissue-specific gene regulatory activity.
Dragon Pharma Ovagen's research profile is distinguished by two well-characterized biological activities documented in peer-reviewed literature. The first is its role in hepatocyte and gastrointestinal epithelial biology, where the EDL sequence interacts with tissue-specific gene programs through PepT1/SLC15A1 transporter-mediated uptake and subsequent nuclear chromatin interaction. The second is its precisely characterized competitive inhibition of HIV-1 protease in vitro, with a documented Ki value of approximately 50 μM — one of the most rigorously quantified biochemical activities established for any ultrashort peptide in the Khavinson catalog, providing a defined molecular binding reference for structure-activity research.
Dragon Pharma manufactures Ovagen to research-grade specifications with ≥99% HPLC purity and LC-MS sequence confirmation per batch. Every Dragon Pharma Ovagen vial ships with an independent third-party Certificate of Analysis. For research use only.
Dragon Pharma Ovagen — Product Specifications
| Parameter |
Detail |
| Abbreviation |
EDL |
| Peptide Type |
Synthetic tripeptide bioregulator — Khavinson cytogen series |
| Sequence |
H-Glu-Asp-Leu-OH |
| Tissue Target |
Liver (hepatic) and gastrointestinal epithelium |
| Molecular Formula |
C15H25N3O8 |
| Molecular Weight |
375.37 g/mol |
| PubChem CID |
444128 |
| HIV-1 Protease Ki |
~50 μM (competitive inhibition, in vitro) |
| Form |
Lyophilized powder |
| Purity |
≥99% (HPLC, Dragon Pharma batch standard) |
| Identity Verification |
LC-MS (Glu-Asp-Leu sequence + 375.37 g/mol confirmed) |
| COA |
Independent third-party, per Dragon Pharma batch |
| Storage (dry) |
-20°C, protect from light; 24+ months |
| Storage (reconstituted) |
2–8°C, 28 days |
| Research Use |
In vitro research only |
Product Identification — Dragon Pharma Ovagen vs Other Named Products: Dragon Pharma Ovagen is the tripeptide bioregulator Glu-Asp-Leu (EDL), developed by Professor Khavinson for liver and gastrointestinal research. A separately named commercial product contains ovine (sheep) follicle-stimulating hormone (FSH) and serves an entirely different function. Verify PubChem CID 444128 and the H-Glu-Asp-Leu-OH peptide sequence before ordering. Dragon Pharma Ovagen is supplied for research use only.
Four Research Angles for Dragon Pharma Ovagen
1. Hepatocyte Biology and Liver Research
Dragon Pharma Ovagen's primary tissue target is the liver. Within the Khavinson cytogen framework, the EDL sequence is proposed to function as an endogenous liver-specific regulatory signal that maintains hepatocyte gene expression programs through direct chromatin interaction. PepT1/SLC15A1 transporters — expressed at high density in hepatocytes and gastrointestinal epithelial cells — mediate selective uptake of the EDL tripeptide, providing the biochemical basis for tissue specificity that distinguishes Dragon Pharma Ovagen from broad-acting peptides.
In aged hepatocyte culture models, the EDL sequence has been studied for protein synthesis restoration and recovery of intracellular biosynthetic rhythm — the cyclical pattern of protein production that becomes disrupted during cellular aging. Research applications include hepatocyte gene expression studies, age-related hepatic decline modeling, hepatoprotective compound screening in experimental hepatitis models, and liver-gut axis biology investigations.
2. Gastrointestinal Epithelial Research
Dragon Pharma Ovagen's tissue selectivity extends to the gastrointestinal epithelium, where PepT1/SLC15A1 transporter expression enables selective cellular uptake of the EDL sequence. GI research applications include mucosal barrier integrity studies, intestinal epithelial cell differentiation modeling, gastric mucosa protection signaling pathway investigation, digestive enzyme regulation research, and inflammatory cytokine modulation in intestinal tissue models. The coordinated liver-gut axis biology accessible through Dragon Pharma Ovagen makes it relevant for research programs examining hepato-gastrointestinal signaling in a single compound.
3. HIV-1 Protease Inhibition and Enzyme Research
The most rigorously characterized biochemical activity of Dragon Pharma Ovagen's EDL sequence comes from published HIV-1 protease inhibition research. Louis, Dyda, Nashed, Kimmel, and Davies (1998, Biochemistry) established through kinetic analysis that Glu-Asp-Leu functions as a competitive inhibitor of mature HIV-1 protease with a Ki value of approximately 50 μM — derived from the viral transframe region (TFR) of Gag-Pol. The EDL tripeptide represents one of the smallest potent analogues of the transframe octapeptide (TFP) that naturally occurs at the N-terminus of the HIV-1 transframe region.
For comparative context, the closely related tripeptide Glu-Asp-Phe demonstrates even greater inhibitory potency at approximately 20 μM Ki, making the EDL/EDF pair a natural structure-activity reference set for protease inhibition mechanism research. This well-defined Ki value makes Dragon Pharma Ovagen one of the few ultrashort peptides in the Khavinson catalog with a precisely quantified enzyme inhibition endpoint available for experimental design and result calibration.
4. Chromatin Remodeling and Epigenetic Research
Consistent with the broader Khavinson bioregulator model, Dragon Pharma Ovagen's EDL sequence is studied for nuclear chromatin interaction and epigenetic gene activation in aging cell models. Research has examined the peptide's capacity to induce decondensation of pericentromeric heterochromatin in aged lymphocyte cultures, activate nucleolar organizing regions (NORs) responsible for ribosomal RNA production, and modulate chromosomal activity in cardiovascular disease models. This chromatin remodeling activity provides a mechanistic research axis for Dragon Pharma Ovagen's hepatic gene regulatory effects, proposing that tissue-specific protein synthesis restoration in aged hepatocytes occurs through direct chromatin accessibility changes rather than receptor-mediated signaling.
Dragon Pharma Ovagen vs Dragon Pharma Livagen: Key Differences
| Feature |
Dragon Pharma Ovagen (EDL) |
Dragon Pharma Livagen (KEDA) |
| Peptide length |
Tripeptide (3 residues) |
Tetrapeptide (4 residues) |
| Sequence |
H-Glu-Asp-Leu-OH |
H-Lys-Glu-Asp-Ala-OH |
| Molecular weight |
375.37 g/mol |
461.5 g/mol |
| Primary tissue target |
Liver and GI epithelium |
Liver and immune cells |
| HIV-1 protease Ki |
~50 μM (documented) |
Not characterized |
| Research relationship |
Complementary — distinct chromatin specificity |
Complementary — distinct chromatin specificity |
| Common use |
Often studied in parallel with Dragon Pharma Livagen in hepatic models |
Often studied in parallel with Dragon Pharma Ovagen in hepatic models |
Dragon Pharma supplies both Dragon Pharma Ovagen (EDL) and Dragon Pharma Livagen (KEDA) from its Khavinson cytogen catalog, enabling parallel comparative hepatic research protocols from a consistent manufacturing source. Both compounds are liver-targeted but mechanistically distinct — they modulate different chromatin subtypes and are used as complementary rather than redundant research tools.
Key Features of Dragon Pharma Ovagen
- ✔ Dragon Pharma pharmaceutical-grade manufacturing — consistent production standards applied across Dragon Pharma's full Khavinson cytogen peptide catalog
- ✔ ≥99% purity by Dragon Pharma batch HPLC standard — exceeds research-grade threshold for hepatic biology and enzyme inhibition assay applications
- ✔ LC-MS sequence identity confirmed per batch — verifies Glu-Asp-Leu at 375.37 g/mol; PubChem CID 444128 confirmed; distinguishes Dragon Pharma Ovagen from related EDX tripeptide variants
- ✔ Published Ki value: ~50 μM HIV-1 protease (competitive) — one of the only ultrashort Khavinson peptides with a precisely quantified enzyme inhibition endpoint available for experimental design calibration
- ✔ Dual liver + GI tissue targeting via PepT1/SLC15A1 — transporter-mediated selectivity provides a mechanistic basis for tissue-specific research applications in both hepatic and intestinal cell models
- ✔ Chromatin remodeling activity — heterochromatin decondensation and NOR activation in aged cell models; connects EDL to epigenetic aging research beyond classical hepatic biology
- ✔ Dragon Pharma Livagen (KEDA) available for parallel comparative protocols — Dragon Pharma supplies both liver-targeted Khavinson bioregulators from consistent manufacturing for comparative chromatin specificity research
- ✔ Independent third-party COA per Dragon Pharma batch — lot-traceable documentation; not in-house or reused across production runs
Product Summary
Dragon Pharma Ovagen is a synthetic tripeptide bioregulator (H-Glu-Asp-Leu-OH / EDL, PubChem CID 444128, MW 375.37 g/mol) manufactured by Dragon Pharma as the liver and gastrointestinal-targeted member of the Khavinson cytogen peptide series. It is characterized by PepT1/SLC15A1-mediated selective tissue uptake, documented competitive inhibition of HIV-1 protease in vitro (Ki ~50 μM), chromatin remodeling and NOR activation in aged cell models, and hepatocyte protein synthesis restoration in preclinical aging research. Dragon Pharma supplies Ovagen alongside Dragon Pharma Livagen (KEDA) for comparative liver bioregulator research from consistent pharmaceutical-grade manufacturing. Purity ≥99% by HPLC, LC-MS sequence confirmed per batch, independent third-party COA per Dragon Pharma production run. For research use only.
Research domains: Hepatic biology • Gastrointestinal epithelial research • HIV-1 protease enzyme inhibition • Chromatin remodeling and epigenetics • Liver-gut axis biology • Comparative Khavinson cytogen protocols
